HER2 MNSCLC market size is expected to grow immensely with a significant CAGR during the study period (2019–2032). Request for free Sample report.

HER2 mNSCLC Market Size Analysis Report 2032 | HER2 MNSCLC Companies

1. Key Insights
2. Report Introduction
3. Key Highlights
4. Executive Summary
5. HER2 mNSCLC Market Overview at a Glance
5.1. Market Share (%) Distribution by Therapies in 2019
5.2. Market Share (%) Distribution by Therapies in 2032
6. Key Events
7. Epidemiology and Market Forecast Methodology
8. Disease Background and Overview
8.1. Introduction
8.1.1. Cellular Classification of NSCLC
8.1.2. Signs and Symptoms of NSCLC
8.1.3. Risk Factors of Lung Cancer
8.1.4. Causes of NSCLC
8.1.5. Disease Biology: NSCLC
9. Diagnosis of NSCLC
9.1. Stages of NSCLC
9.2. Staging System
10. Current Treatment Practices: NSCLC
10.1. Chemotherapy
10.2. Targeted Therapy
10.3. Immunotherapy
10.4. Surgery
10.5. Radiation Therapy
10.6. Stage-wise Treatment Options of NSCLC
11. Treatment Guidelines and Recommendations for Non-small Cell Lung Cancer (NSCLC)
11.1. NCCN Guideline for NSCLC
11.2. ESMO Guideline for Non-small Cell Lung Cancer (NSCLC)
11.3. Japanese Guidelines for Non-small Cell Lung Cancer (NSCLC)
11.4. Biomarkers Testing Recommendations
12. Epidemiology and Patient Population
12.1. Key Findings
12.2. Assumptions and Rationale: The 7MM
12.3. Total Incident Cases of NSCLC in the 7MM
12.4. The United States
12.4.1. Total Incident Cases of NSCLC in the United States
12.4.2. Gender-specific Cases of NSCLC in the United States
12.4.3. Age-specific Cases of NSCLC in the United States
12.4.4. Total Incident Cases of NSCLC by Histology in the United States
12.4.5. Total Incident Cases of NSCLC by Stage (at diagnosis) in the United States
12.4.6. Total Cases of NSCLC by Genetic Mutations/Biomarkers in the United States
12.4.7. Line-wise Treated Cases of Metastatic NSCLC in the United States
12.5. EU4 and the UK
12.5.1. Total Incident Cases of NSCLC in EU4 and the UK
12.5.2. Gender-specific Cases of NSCLC in EU4 and the UK
12.5.3. Age-specific Cases of NSCLC in EU4 and the UK
12.5.4. Total Incident Cases of NSCLC by Histology in EU4 and the UK
12.5.5. Total Incident Cases of NSCLC by Stage (at diagnosis) in EU4 and the UK
12.5.6. Total Cases of NSCLC by Genetic Mutations/Biomarkers in EU4 and the UK
12.5.7. Line-wise Treated Cases of Metastatic NSCLC in EU4 and the UK
12.6. Japan Epidemiology
12.6.1. Total Incident Cases of NSCLC in Japan
12.6.2. Gender-specific Cases of NSCLC in Japan
12.6.3. Age-specific Cases of NSCLC in Japan
12.6.4. Total Incident Cases of NSCLC by Histology in Japan
12.6.5. Total Incident Cases of NSCLC by Stage (at diagnosis) in Japan
12.6.6. Total Cases of NSCLC by Genetic Mutations/Biomarkers in Japan
12.6.7. Line-wise Treated Cases of Metastatic NSCLC in Japan
13. Patient Journey
14. Key Endpoints in NSCLC
15. Marketed Drugs
15.1. Key Competitors
15.2. ENHERTU (trastuzumab deruxtecan): Daiichi Sankyo/AstraZeneca
15.2.1. Product Description
15.2.2. Regulatory Milestones
15.2.3. Other Developmental Activities
15.2.4. Pivotal Clinical Trials
15.2.5. Current Pipeline Activity
15.2.6. Safety and Efficacy
15.2.7. Product Profile
16. Emerging Drugs
16.1. Key Competitors
16.2. Pyrotinib: Jiangsu HengRui Medicine
16.2.1. Product Description
16.2.2. Clinical Development
16.3. Sunvozertinib: Dizal Pharmaceutical
16.3.1. Product Description
16.3.2. Other Developmental Activities
16.3.3. Clinical Development
16.3.4. Safety and Efficacy
17. HER2 mNSCLC: The 7MM Market Analysis
17.1. Key Findings
17.1.1. Total Market Size of HER2 NSCLC&nbsp; in the 7MM
17.2. Market Outlook
17.3. Key Market Forecast Assumptions
17.4. The United States Market Size
17.4.1. Total Market Size of HER2 mNSCLC in the United States
17.4.2. Market Size of HER2 mNSCLC by Therapies in the United States
17.5. EU4 and the UK Market Size
17.5.1. Total Market Size of HER2 mNSCLC in EU4 and the UK
17.5.2. Market Size of HER2 mNSCLC by Therapies in EU4 and the UK
17.6. Japan Market Size
17.6.1. Total Market Size of HER2 mNSCLC in Japan
17.6.2. Market Size of HER2 mNSCLC by Therapies in Japan
18. Unmet Needs
19. SWOT Analysis
20. KOL Views
21. Market Access and Reimbursement
21.1. Patient Access Program
21.2. Institute for Quality and Efficiency in Health Care (IQWiG): Germany
21.3. HER2 NSCLC Reimbursement in France
21.4. Italian Medicines Agency (AIFA): Italy
21.5. HER2 NSCLC Reimbursement in Spain
21.6. National Institute for Health and Care Excellence (NICE): The UK
21.7. Reimbursement Status of Lung Cancer Drugs in Japan
22. Appendix
22.1. Bibliography
22.2. Report Methodology
23. DelveInsight Capabilities
24. Disclaimer
 
25. About DelveInsight

HER2 Metastatic Non-small Cell Lung Cancer Market

HER2 Metastatic Non-small Cell Lung Cancer – Market Insights, Epidemiology, and Market Forecast – 2032

DelveInsight's HER2 MNSCLC Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the HER2 MNSCLC, historical and forecasted epidemiology